China Biologic Products (CBPO) is one of the leading biopharmaceutical companies in the world. It was founded in 1971 and is headquartered in Beijing, China. The company specializes in the research, development, production, and sale of plasma-based biopharmaceutical products.
CBPO's product portfolio includes plasma-derived products such as human albumin, immunoglobulin, coagulation factor VIII and IX, and fibrinogen. These products are used for the treatment of various diseases such as immune disorders, hemophilia, and shock or trauma.
CBPO places a strong emphasis on research and development and has established a comprehensive R&D system. It has invested heavily in technology research and innovation, as well as talent development. CBPO's R&D team consists of over 600 scientists, including professionals with doctoral degrees and extensive experience in various fields.
CBPO has a state-of-the-art manufacturing facility in China that meets international standards for quality and safety. The facility has an annual production capacity of 700 tons of plasma-based products and is equipped with advanced technology for large-scale production, purification, and testing.
CBPO has established strategic partnerships with other leading pharmaceutical companies to expand its product portfolio and distribution network. For example, in 2019, CBPO entered into a strategic partnership with Sanquin, the blood supply organization in the Netherlands, to jointly develop new plasma-based products.
In 2020, CBPO's total revenue was approximately $652 million, representing an increase of 7.9% from the previous year. Its net income was $169 million, representing an increase of 4.8% from the previous year. CBPO's strong financial performance is a reflection of its strong product portfolio, R&D capabilities, and strategic partnerships.
China Biologic Products is a leader in the biopharmaceutical industry with a strong focus on research and development, manufacturing capabilities, and strategic partnerships. Its commitment to innovation and quality has enabled the company to establish a strong reputation, both locally and internationally. With its well-diversified product portfolio and expanding distribution network, CBPO is well-positioned for continued growth and success in the future.
